Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) - Phase 2 Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations: Sub-protocol EAY131-M. (October 2022) - Hays, J.; Song, Z.; Paik, P.; Iyer, G.; Mitchell, E.; Wright, J.; Doyle, L.; Gray, R.; Wang, V.; McShane, L.; Rubinstein, L.; Patton, D.; et al.